BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Week in Review: OriGene Technologies Acquires Zhongshan Biotech


3/19/2012 9:22:23 AM

March 17, 2012 -- OriGene Technologies, a US research tool maker, acquired Beijing Zhongshan Golden Bridge Biotech, which makes oncology pathology products; Zhejiang Hisun Pharma and Piedmont Pharma of the US will jointly develop products for the pet segment of the animal health market; China has allocated $8 million to set up a Global Clinical Trial and Research Center in Tianjin Biotechnology Research Park; China’s aggressive cost-cutting of drug prices, especially generics, has put a cloud over the country’s drug makers; Beijing has closed the pharmacies in two of its 22 public hospitals on a trial basis to implement a healthcare reform goal; Boehringer Ingelheim will invest $15.7 million to build an R&D center in Shanghai’s Zhangjiang HiTech Park; Bayer Healthcare plans to increase its China revenues up to $3.3 billion by 2015; InflammaGen™ Therapeutics is planning a China strategy with help from ChinaBio®; and Sihuan Pharma’s application to begin clinical trials of a new treatment for hypertension was accepted by the SFDA. More details….

Stock Symbols: (SHE: 600267) (HK: 0460)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES